Extended Data Fig. 1: Response assessment per FDG-PET/CT and CT in relation to pathological response and nodal upstaging. | Nature Medicine

Extended Data Fig. 1: Response assessment per FDG-PET/CT and CT in relation to pathological response and nodal upstaging.

From: Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Extended Data Fig. 1

Metabolic responses (PERCIST), radiographic responses (RECIST), nodal upstaging (yes, no), pathological response category (Viable tumor cells), and treatment arm (A – nivolumab, B – nivolumab/relatlimab) of 30 patients from study site Essen, who underwent FDG-PET/CT scanning following preoperative immunotherapy. One patient was excluded because surgery was aborted due to pleural carcinosis.

Back to article page